Cargando…

Improved Survival for Patients with Systemic Sclerosis–associated Pulmonary Arterial Hypertension: For Real?

Detalles Bibliográficos
Autor principal:	Xanthouli, Panagiota
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896648/ https://www.ncbi.nlm.nih.gov/pubmed/36383981 http://dx.doi.org/10.1164/rccm.202210-2006ED

Ejemplares similares

Hypochromic red cells as a prognostic indicator of survival among patients with systemic sclerosis screened for pulmonary hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2023)

Oxygenated hemoglobin as prognostic marker among patients with systemic sclerosis screened for pulmonary hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2023)

Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up
por: Xanthouli, Panagiota, et al.
Publicado: (2020)

The Importance of Echocardiographic Screening for Pulmonary Arterial Hypertension in Korean Patients with Systemic Sclerosis
por: Kim, Hack-Lyoung
Publicado: (2016)

Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era
por: Launay, David, et al.
Publicado: (2013)

Prognostic impact of hypochromic erythrocytes in patients with pulmonary arterial hypertension
por: Xanthouli, Panagiota, et al.
Publicado: (2021)

Tolerability, safety and survival in patients with severe pulmonary arterial hypertension treated with intravenous epoprostenol (Veletri(®)): a prospective, 6-months, open label, observational, non-interventional study
por: Degering, Julia, et al.
Publicado: (2023)

Twelve-Year Survival in a Patient With Systemic Sclerosis–Associated Pulmonary Arterial Hypertension on Nifedipine Monotherapy
por: Helgeson, Scott A., et al.
Publicado: (2019)

Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
por: Guillén-Del-Castillo, Alfredo, et al.
Publicado: (2022)

Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension
por: Morrisroe, Kathleen, et al.
Publicado: (2017)

Management of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
por: Almaaitah, Saja, et al.
Publicado: (2020)

Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension
por: Mismetti, Valentine, et al.
Publicado: (2023)

Profiles and treatment patterns of patients with pulmonary arterial hypertension on monotherapy at experienced centres
por: Wissmüller, Max, et al.
Publicado: (2022)

Phenotyping pulmonary hypertension in systemic sclerosis: a moving target
por: Mercurio, Valentina, et al.
Publicado: (2018)

Screening for pulmonary arterial hypertension in systemic sclerosis
por: Weatherald, Jason, et al.
Publicado: (2019)

Clinical features of pulmonary arterial hypertension associated with systemic sclerosis
por: Tuhy, Tijana, et al.
Publicado: (2023)

Right heart size and function significantly correlate in patients with pulmonary arterial hypertension – a cross-sectional study
por: Fischer, Lukas, et al.
Publicado: (2018)

Severity of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension in African Americans
por: Blanco, Isabel, et al.
Publicado: (2014)

Socioeconomic status and survival in patients with pulmonary hypertension
por: Ong, Mei-Sing
Publicado: (2020)

Author Correction: Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension
por: Guillén-Del-Castillo, Alfredo, et al.
Publicado: (2022)

Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis
por: Fairley, Jessica L., et al.
Publicado: (2023)

What is pulmonary arterial hypertension?
por: Rich, Stuart
Publicado: (2012)

The revolution of pulmonary arterial hypertension
por: Harari, Sergio
Publicado: (2016)

Is iron deficiency caused by BMPR2 mutations or dysfunction in pulmonary arterial hypertension patients?
por: Theobald, Vivienne, et al.
Publicado: (2023)

Right Ventricle to Pulmonary Artery Coupling Predicts the Risk Stratification in Patients With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
por: Lai, Jinzhi, et al.
Publicado: (2022)

Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA
por: Ratanawatkul, Pailin, et al.
Publicado: (2020)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

The expression profiling of microRNA in systemic sclerosis-associated pulmonary arterial hypertension
por: Huang, Yu-Xia, et al.
Publicado: (2021)

Circulating plasma microRNAs in systemic sclerosis-associated pulmonary arterial hypertension
por: Wuttge, Dirk M, et al.
Publicado: (2021)

Selenium and Copper as Biomarkers for Pulmonary Arterial Hypertension in Systemic Sclerosis
por: Sun, Qian, et al.
Publicado: (2020)

The role of pulmonary arterial hypertension-targeted therapy in systemic sclerosis
por: Lee, Michael H, et al.
Publicado: (2019)

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension
por: Weatherald, Jason, et al.
Publicado: (2023)

The success of pulmonary hypertension treatment: improved cardiac function by reducing the arterial load
por: Vonk-Noordegraaf, Anton, et al.
Publicado: (2018)

Contemporary survival of patients with pulmonary arterial hypertension and congenital systemic to pulmonary shunts
por: Vijarnsorn, Chodchanok, et al.
Publicado: (2018)

Unique Predictors of Mortality in Patients With Pulmonary Arterial Hypertension Associated With Systemic Sclerosis in the REVEAL Registry
por: Chung, Lorinda, et al.
Publicado: (2014)

MiRNAs in Systemic Sclerosis Patients with Pulmonary Arterial Hypertension: Markers and Effectors
por: Zaaroor Levy, Mor, et al.
Publicado: (2022)

Reduction of BMPR2 mRNA Expression in Peripheral Blood of Pulmonary Arterial Hypertension Patients: A Marker for Disease Severity?
por: Theobald, Vivienne, et al.
Publicado: (2022)

Early treatment with ambrisentan of mildly elevated mean pulmonary arterial pressure associated with systemic sclerosis: a randomized, controlled, double-blind, parallel group study (EDITA study)
por: Pan, Zixuan, et al.
Publicado: (2019)

Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis
por: Launay, David, et al.
Publicado: (2018)

Pregnancy in Patients with Pulmonary Arterial Hypertension “To Deliver, or Not to Deliver: That Is the Question”
por: Park, Jae-Hyeong
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_budanmtpfjcrmo36rdf2ok5c97